Drugs / fosdagrocorat
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01362673 | May → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01199900 | Aug → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00987038 | Sep → Dec 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00812825 | Jan → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01393639 | Sep 2011 → Jun 2014 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00938587 | Oct 2009 → Jul 2010 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fosdagrocorat | “PF-04171327 (fosdagrocorat) is a phosphate ester prodrug of PF-00251802 (dagrocorat), a selective high-affinity partial agonist of the glucocorticoid receptor” PMID 29112329 ↗ Nov 20171“fosdagrocorat (PF-04171327), a dissociated agonist of the” PMID 31168411 ↗ Apr 2019 |
| Known as | PF-04171327 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01362673 ↗ |
| Modality | Small molecule | — CHEMBL3137316 ↗ |
| Route | Oral | “One 25 mg tablet administered once a day for 15 days” NCT00987038 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor modulator” CHEMBL3137316 ↗ |